Document Detail

Drug insight: role of the androgen receptor in the development and progression of prostate cancer.
MedLine Citation:
PMID:  17392714     Owner:  NLM     Status:  MEDLINE    
Functional androgen receptor (AR) signaling is necessary for the development of prostate cancer. The therapeutic effect of androgen deprivation therapy for prostate cancer was described over 60 years ago and this treatment remains the mainstay of systemic therapy despite its transient response duration. It has become clear that AR expression and signaling remains intact as the disease evolves from androgen-sensitive cancer to classically (but perhaps inaccurately) termed hormone refractory prostate cancer. Through several genetic and epigenetic adaptations, prostate tumors continue to rely on AR growth signaling and they thus remain targets of 'hormonal' therapy. The development of new strategies and drugs that can abrogate AR signaling will probably result in important clinical benefits. The biology of androgen independence and the development of new approaches targeting AR signaling are reviewed herein.
Mary-Ellen Taplin
Related Documents :
9444954 - Alternative splicing of fibroblast growth factor receptor 2 (fgf-r2) in human prostate ...
19552894 - Characterization of the intra-prostatic immune cell infiltration in androgen-deprived p...
17932034 - Induction of the sumo-specific protease 1 transcription by the androgen receptor in pro...
16978674 - Liquid chromatography-mass spectrometric assay of androstenediol in prostatic tissue: i...
2346284 - Monitoring cancer incidence and risk factors in singapore.
23270564 - Fgfr-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Nature clinical practice. Oncology     Volume:  4     ISSN:  1743-4262     ISO Abbreviation:  -     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-03-29     Completed Date:  2007-04-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101226509     Medline TA:  Nat Clin Pract Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  236-44     Citation Subset:  IM    
Harvard Medical School, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Androgen Antagonists / pharmacology,  therapeutic use*
Disease Progression
Drug Resistance, Neoplasm
Prostatic Neoplasms / drug therapy,  metabolism*,  pathology
Receptors, Androgen / physiology*
Signal Transduction
Reg. No./Substance:
0/Androgen Antagonists; 0/Receptors, Androgen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylact...
Next Document:  Technology insight: cytotoxic drug immunoconjugates for cancer therapy.